Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388).

ABSTRACT:

Rationale

The risk of recurrence following a stroke or transient ischemic attack is high, especially immediately after the event.

Hypothesis

Because two antiplatelet agents are superior to one in patients with non-cardioembolic events, more intensive treatment might be even more effective.

Sample size estimates

The sample size of 4100 patients will allow a shift to less recurrence, and less severe recurrence, to be detected (odds ratio 0·68) with 90% power at 5% significance.

Methods and design

Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (ISRCTN47823388) is comparing the safety and efficacy of intensive (combined aspirin, clopidogrel, and dipyridamole) vs. guideline antiplatelet therapy, both given for one-month. This international colla

SUBMITTER: TARDIS Trial Investigators 

PROVIDER: S-EPMC4855643 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature